Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma
Pectasides E, Stachler M, Derks S, Liu Y, Maron S, Islam M, Alpert L, Kwak H, Kindler H, Polite B, Sharma M, Allen K, O'Day E, Lomnicki S, Maranto M, Kanteti R, Fitzpatrick C, Weber C, Setia N, Xiao S, Hart J, Nagy R, Kim K, Choi M, Min B, Nason K, O'Keefe L, Watanabe M, Baba H, Lanman R, Agoston A, Oh D, Dunford A, Thorner A, Ducar M, Wollison B, Coleman H, Ji Y, Posner M, Roggin K, Turaga K, Chang P, Hogarth K, Siddiqui U, Gelrud A, Ha G, Freeman S, Rhoades J, Reed S, Gydush G, Rotem D, Davison J, Imamura Y, Adalsteinsson V, Lee J, Bass A, Catenacci D. Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma. Cancer Discovery 2018, 8: cd-17-0395. PMID: 28978556, PMCID: PMC5894850, DOI: 10.1158/2159-8290.cd-17-0395.Peer-Reviewed Original ResearchConceptsCell-free DNAGastroesophageal adenocarcinomaPrimary tumorMetastatic lesionsMetastatic tumorsTargeted therapyGenomic alterationsGenomic biomarkersAnalysis of cell-free DNACell-free DNA profilingSynchronous metastatic lesionsGenomic profiling resultsTargetable genomic alterationsSelection of therapyClinically relevant alterationsGenomic heterogeneityPrecision medicineUntreated metastasesDisseminated diseaseMultiregional sequencingMetastatic tissuesTargetable alterationsBiomarker testingRelevant alterationsTissue profile
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply